Frontlight ResearchEarly access
CompletedNo phase
Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab
Key facts
- Who runs it
- Daewoong Pharmaceutical Co. LTD.
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 10,067 people enrolled
- Started
- 6 Jul 2022
- Ended
- 8 Nov 2024
- Type of study
- Observational
- Treatments tested
- Fexuprazan
- Record updated
- 24 January 2025
Who can take part
- Age
- 19 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Adult aged 19 years to 75 years (on registration date)
- Patient scheduled to administer Fexuclue tablet based on the medical judgment of investigator
- Patient who agreed to participate in this observation study and signed Informed Consent Form
Who cannot take part
- A person who participates in another clinical trial and is administering (applying) clinical trial drugs or clinical trial medical devices
- A person who falls under the prohibition of administration according to the permission for Fexuclue Tablet; Patients with hypersensitivity to the components of Fexuclue tablet or Fexuclue tablet and a history thereof; Patients undergoing Atazanavir, Nelfinavir or Lilpivirin-containing preparations; Pregnant and lactating women; Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabortion
- In addition to the above, a person who has determined that the researcher (the doctor in charge) is not suitable for participation in this observation study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This observational study is a large-scale, prospective, and multi-institutional observational study.
Read full original descriptionShow less
Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration of Pexuclue tablet.
The group in the trial
- Treatment group
treated with Fexuclue Tablet 40mg
Treatment: Fexuprazan
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-Center, Prospective, Observational Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab. in Patients With Erosive Gastroesophageal Reflux Disease
- Record updated
- 24 January 2025